|
InterMune Stage: Venture Date of Investment: 2000 Web Site : http://www.intermune.com Stock Symbol : NASDAQ: ITMN |
 |
InterMune, Inc., is an independent biopharmaceutical company focused on developing and commercializing innovative therapies in pulmonology and hepatology. The company was founded in 1999 with a strategy of acquiring clinical-stage products that could benefit from increased development and commercial focus within targeted therapeutic areas. Warburg Pincus led InterMune's second round of private financing in 2000 to help fund such product acquisitions and the execution of clinical trials for, and commercialization of, new product indications. InterMune holds the rights in the U.S. and Japan to develop and market interferon-gamma, a protein involved in the regulation of a variety of immune and fibrotic (scarring) processes. Interferon-gamma is currently approved and on the market in the U.S. for the treatment of two rare congenital disorders and InterMune intends to develop and commercialize new and much larger indications for the drug. The company's most advanced opportunity involves the use of interferon-gamma to treat idiopathic pulmonary fibrosis (IPF). In 2001, InterMune bolstered its product portfolio with the acquisition of Infergen (or consensus interferon), a marketed product for the treatment of Hepatitis C, from Amgen. InterMune completed its initial public offering in March 2000.
